HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia

Background Thrombocytopenia is a common adverse event on HER2-targeted therapies, fam-trastuzumab deruxtecan (T-DXd) and ado-trastuzumab emtansine (T-DM1). A reported association of Asian ancestry with this event merits investigation to rule out potential confounding. Methods Subjects in this retros...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer (Tokyo, Japan) Japan), 2023-09, Vol.30 (5), p.796-801
Hauptverfasser:	Rainone, Michael, Behrendt, Carolyn E., Kasparian, Saro, Nguyen, Tina, Sedrak, Mina S., Lavasani, Sayeh, Stewart, Daphne B., Yuan, Yuan, Mortimer, Joanne E., Waisman, James R., Patel, Niki, Pullarkat, Vinod
Format:	Artikel
Sprache:	eng
Schlagworte:	Ado-Trastuzumab Emtansine - adverse effects Analysis Antibodies Biopharmaceutics Breast cancer Breast Neoplasms - pathology Cancer Research Cycling Drug therapy Female Health aspects Humans Immunoconjugates - therapeutic use Maytansine Medicine Medicine & Public Health Metastasis Oncology Original Original Article Receptor, ErbB-2 - genetics Retrospective Studies Surgery Surgical Oncology Thrombocytopenia Thrombocytopenia - chemically induced Thrombocytopenia - drug therapy Trastuzumab - therapeutic use Viral antibodies Women
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!